AgomAb Therapeutics (NASDAQ:AGMB) Shares Down 6.3% – Should You Sell?

AgomAb Therapeutics NV (NASDAQ:AGMB)’s share price dropped 6.3% on Thursday . The company traded as low as $14.00 and last traded at $14.0150. 59,191 shares changed hands during mid-day trading, a decline of 56% from the average session volume of 134,962 shares. The stock had previously closed at $14.96.

Analyst Ratings Changes

A number of research firms recently issued reports on AGMB. B. Riley Financial began coverage on shares of AgomAb Therapeutics in a research note on Thursday, July 23rd. They issued a “buy” rating and a $34.00 target price on the stock. HC Wainwright started coverage on shares of AgomAb Therapeutics in a research report on Monday, June 22nd. They set a “buy” rating and a $35.00 target price for the company. Wall Street Zen cut shares of AgomAb Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Piper Sandler initiated coverage on AgomAb Therapeutics in a research note on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 price objective on the stock. Finally, Cantor Fitzgerald assumed coverage on AgomAb Therapeutics in a research report on Wednesday, August 19th. They set an “overweight” rating for the company. Seven equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $37.50.

AgomAb Therapeutics Stock Performance

The stock’s 50-day moving average is $13.41 and its 200-day moving average is $12.51.

AgomAb Therapeutics (NASDAQ:AGMB) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share for the quarter. On average, analysts expect that AgomAb Therapeutics NV will post -1.76 EPS for the current fiscal year.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.